GlobeNewswire Inc | Feb 19, 2021 01:30AM EST

February 19, 2021

Montrouge, France, February 19, 2021

DBV Technologies to Participate in SVB Leerink Global Partners Healthcare Conference

DBV Technologies (Euronext: DBV ISIN: FR0010417345 Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that Daniel Tass, Chief Executive Officer, will participate in a fireside chat at the virtual SVB Leerink Global Partners Healthcare Conference on Wednesday, February 24th at 8am ET.

A live webcast of the fireside chat at the SVB Leerink Global Partners Healthcare Conference will be available on the Investors & Media section of the Companys website: https://www.dbv-technologies.com/investor-relations/. A replay of the presentation will also be available on DBVs website after the event.

About DBV TechnologiesDBV Technologies is developing Viaskin, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT, DBVs method of delivering biologically active compounds to the immune system through intact skin. With this new class of non-invasive product candidates, the Company is dedicated to safely transforming the care of food allergic patients. DBVs food allergies programs include ongoing clinical trials of Viaskin Peanut. DBV Technologies has global headquarters in Montrouge, France and offices in Bagneux, France, and North American operations in Summit, NJ and New York, NY. The Companys ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), and the Companys ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT).

Investor Contact Anne PollakDBV Technologies+1 857-529-2363anne.pollak@dbv-technologies.com

Media ContactAngela MarcucciDBV Technologies+1646-842-2393angela.marcucci@dbv-technologies.com

Attachment

-- PDF Version